# US 2023/0271966 A1 · Prpk inhibitors

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0271966 A1
- Document ID: US20230271966A1
- Status: Published application
- Kind: A1
- Application number: 18/013,106
- Filed: 2021-06-28
- Published: 2023-08-31
- Earliest claimed: 2020-06-29
- Assignees: Dana-Farber Cancer Institute, Inc.
- Applicants: Dana-Farber Cancer Institute, Inc.
- Inventors: Kenneth C. Anderson; Teru Hideshima; Sirano Dhe-Paganon; Hyuk-Soo Seo; Takashi Mizutani; Tinghu Zhang
- Web page: https://patentgrep.com/patent/US20230271966A1

## CPC

- C07D 487/04: Ortho-condensed systems
- A61P 35/00: Antineoplastic agents
- C07D 401/04: directly linked by a ring-member-to-ring-member bond
- C07D 401/14: containing three or more hetero rings
- C07D 413/14: containing three or more hetero rings
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

This disclosure relates to compounds of formula (I) as defined in the Specification. This disclosure also relates to methods of synthesizing the compound of formula (I) and using the compounds of formula (I) for treating a disease (e.g., cancer).

## Claims

### Claim 1

A compound of formula (I) or a salt thereof:
wherein
each of R1, R2, R3, and R4, independently, is H, halo, OR, COOR, C(O)R, C(O)N(RR′), NH—S(O)2—R, N(RR′), C1-C10 alkyl, C1-C10 arylalkyl, C2-C10 alkenyl, C2-C10 alkynyl, C3-C20 cycloalkyl, C3-C20 cycloalkenyl, C1-C20 heterocycloalkyl, C1-C20 heterocycloalkenyl, aryl, or heteroaryl; or R1 and R2, together with the carbon atoms to which they are attached, form a group comprising a five-membered or six-membered ring; or R2 and R3, together with the carbon atoms to which they are attached, form a group comprising a five-membered or six-membered ring; or R3 and R4, together with the carbon atoms to which they are attached, form a group comprising a five-membered or six-membered ring;
R5 is H or C1-C10 alkyl optionally substituted by aryl;
each of C1-C10 arylalkyl, C3-Cao cycloalkyl, C3-Cao cycloalkenyl, C1-Cao heterocycloalkyl, C1-C20 heterocycloalkenyl, aryl, heteroaryl, five-membered ring, and six-membered, independently, is optionally substituted by C1-C10 alkyl, halo, OR, or COOR; and
each of R and R′, independently, is H, C1-C10 alkyl, C3-Cao cycloalkyl, C3-Cao heterocycloalkyl, aryl, or heteroaryl;
provided that when one of R1, R2, R3, and R4 is NH2, at least another of R1, R2, R3, and R4 is not H or R5 is not H; and when one of R1 and R4 is OH or OCH3, the other of R1 and R4 is not H, or one of R2 and R3 is not H, or R5 is not H or CH3.

### Claim 2 (depends on 1)

The compound of claim 1, wherein each of R1 and R4, independently, is H, OR, NH—S(O)2—R, N(RR′), or C1-C20 heterocycloalkenyl.

### Claim 3 (depends on 2)

The compound of claim 2, wherein each of R1 and R4, independently, is H, OH, OCH3, NH—S(O)2—CH3, NH2,

### Claim 4 (depends on 1)

The compound of claim 1, wherein each of R2 and R3, independently, is H, halo, OR, COOR, C(O)N(RR′), NH—S(O)2—R, C1-C20 heterocycloalkenyl, or heteroaryl.

### Claim 5 (depends on 4)

The compound of claim 4, wherein each of R2 and R3, independently, is H, Br, OH, COOH, C(O)—(NH)—CH3, C(O)NH2, NH—S(O)2—CH3,

### Claim 6 (depends on 1)

The compound of claim 1, wherein R5 is H or C1-C10 alkyl optionally substituted by aryl, in which the aryl is optionally substituted by COOR.

### Claim 7 (depends on 6)

The compound of claim 6, wherein R5 is H, CH3, CH2CH3, CH(CH3)2, CH2-phenyl, or CH2-(4-methoxycarbonylphenyl).

### Claim 8 (depends on 1)

The compound of claim 1, wherein the compound is one of Compounds 8-35 or a salt thereof.

### Claim 9 (depends on 1)

The compound of claim 1, wherein R1 and R2, together with the carbon atoms to which they are attached, form a group comprising a five-membered or six-membered ring.

### Claim 10 (depends on 9)

The compound of claim 9, wherein R1 and R2, together with the carbon atoms to which they are attached, form

### Claim 11 (depends on 9)

The compound of claim 9, wherein R3 is H or Br.

### Claim 12 (depends on 9)

The compound of claim 9, wherein R4 is H.

### Claim 13 (depends on 9)

The compound of claim 9, wherein R5 is H or CH3.

### Claim 14 (depends on 1)

The compound of claim 1, wherein the compound is one of Compounds 1-7 or a salt thereof.

### Claim 15 (depends on 1)

A pharmaceutical composition, comprising a compound of claim 1 and a pharmaceutically acceptable carrier.

### Claim 16 (depends on 15)

A method for treating cancer in a subject in need thereof, comprising administering to the subject the pharmaceutical composition of claim 15 in an amount effective to treat the cancer.

### Claim 17 (depends on 16)

The method of claim 16, wherein the cancer is multiple myeloma, cervical cancer, colon cancer, or skin cancer.

### Claim 18 (depends on 1)

A method of modulating PRPK activity in a cell, comprising contacting the cell in vitro with a compound of claim 1 in an amount sufficient to modulate PRPK activity.
